4 pharmaceutical companies expect net profit to increase by over 1000% in 2021

Recently listed pharmaceutical companies have been busy in 2021 performance disclosure
.
According to statistics from Flush iFinD, 2,560 companies have announced performance forecasts, of which 238 are companies in the pharmaceutical and biological industry, and 60% of them are pre-happy
.
Judging from the growth rate of net profit of 238 pharmaceutical companies that have disclosed performance forecasts, there are 30 pharmaceutical and biological companies with a net profit increase of more than 100% in 2021.
Among them, 4 pharmaceutical companies are expected to increase their net profit by more than 1000% in 2021.
Jimin Medical, Rejing Bio, Lisheng Pharmaceutical, and Harbin Sanlian
.
Jimin Medical: The lower limit of the expected net profit increase is 2088.
46% Jimin Medical announced on the evening of January 17 that the net profit attributable to shareholders of listed companies in 2021 is expected to be 140 million to 155 million yuan, an increase of 2088.
46 compared with the same period last year.
%~2322.
94%
.
Regarding the reasons for the large increase in net profit in 2021, the company explained that there are mainly three aspects: first, the company's net profit scale was low due to the provision for impairment of goodwill and litigation losses in the previous year; second, the company's safety syringes this year The business increased significantly; thirdly, the company's disposal of Yuncheng New Friendship Hospital confirmed the investment income, and Ezhou Second Hospital reversed part of the litigation losses accrued in the previous period
.
According to the data, Jimin Medical's main business includes three major business segments, namely the research and development, production and sales of medical devices, medical service business, and the research and development, production and sales of large infusion series products
.
Rejing Bio: The lower limit of the expected increase in net profit is 1684.
65% On January 6, Rejing Bio released a performance forecast saying that it is expected to achieve a net profit of 2 billion to 2.
35 billion yuan in 2021, a year-on-year increase of 1684.
65% to 1996.
97%
.
The company stated that the company's operating performance in 2020 was relatively small, resulting in a smaller comparison base with 2021
.
In the first half of 2021, the company's antigen detection kits were certified by the German Federal Institute for Drugs and Medical Devices for free home testing earlier, resulting in an explosive growth in the company's foreign trade orders in the first half of the year; in the second half of 2021, Europe, Southeast Asia, etc.
The demand for antigen detection reagents in countries and regions has increased significantly, resulting in a substantial increase in overseas detection reagent revenue. .
According to public information, Rejing Bio is an enterprise mainly engaged in in vitro diagnostic reagents and instruments.
The company's products are widely used in clinical fields such as liver cancer, hepatitis, cardiovascular and cerebrovascular diseases, and inflammatory infections, as well as in biosafety, food safety, and emergency disease control.
and other areas of public safety
.
Lisheng Pharmaceutical: The lower limit of the expected net profit increase is 1176.
8% Lisheng Pharmaceutical disclosed the performance forecast on the evening of January 21, saying that the net profit in 2021 is expected to be 110 million-140 million yuan, a year-on-year increase of 1176.
8%-1525.
02%
.
Regarding the reasons for the growth in performance, the company stated that during the reporting period, the company actively took effective measures to strengthen budget management and cost control, and compressed various controllable expenses.
In 2021, both sales and management expenses dropped significantly
.
Affected by the centralized maturity and interest settlement of the company's time deposits, the interest income of funds in 2021 increased compared with the previous year
.
According to the data, Lisheng Pharmaceutical has always focused on the pharmaceutical and health industry, adhered to the mission and vision of "devoting itself to the cause of health and sharing a green life", and engaged in the research and development, production and sales of pharmaceutical products
.
Ha Sanlian: The lower limit of the expected net profit increase Ha Sanlian announced on the evening of January 18 that it is expected to achieve a net profit of 349 million yuan to 379 million yuan in 2021, a year-on-year increase of 1090.
12%-1192.
42%
.
Regarding the reasons for the changes in performance, Ha Sanlian said that the contribution of non-recurring gains and losses to the turnaround in performance was large
.
On February 9, 2021, the company reviewed and approved the "Proposal on Foreign Investment with Equity of Wholly-owned Subsidiaries", and reviewed and approved the "Proposal on Foreign Investment with Equity of Wholly-owned Subsidiaries" at the second extraordinary general meeting of shareholders in 2021.
Proposal", in 2021, the company will increase the capital of Harbin Fuerjia Technology Development Co.
, Ltd.
with 100% equity of Harbin Beixing Pharmaceutical Co.
,
Ltd.
The transaction price is based on December 31, 2020 as the evaluation base date.
According to the evaluation results and confirmed by both parties, the value of 100% equity of North Star Pharmaceutical is 570 million yuan. .
According to the data, Hasanlian is a listed pharmaceutical company integrating R&D, production and sales.
The company's products focus on nervous system, cardiovascular, musculoskeletal, systemic anti-infective, basic infusion and nutritional infusion, anti-tumor Drugs and immunomodulators, digestive tract and metabolism and other therapeutic areas
.